- The FDA has advised Acura (OTCQB:ACUR) that data from its AP-ADF-301 intranasal abuse liability study for its Aversion combo drug is "insufficient to support an intranasal abuse deterrence claim."
- Acura says its plans for the drug, including "a revised projected timeline" for submitting an NDA, will be determined following a meeting with the FDA.
- The company adds it's "committed to developing [its] Aversion opiods products."
Acura -6.4% AH after providing update for Aversion
Recommended For You
More Trending News
About ACUR Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ACUR | - | - |
Acura Pharmaceuticals, Inc. |